Disc Medicine Inc

NASDAQ:IRONUnited States

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Contact Information

Headquarters

321 Arsenal Street, Suite 101WATERTOWN, MA, United States 02472

Phone

617-674-9274

Fax

302-655-5049

Executives

Executive Chairman of the Board

Donald Nicholson

President, Chief Executive Officer, Director

John Quisel

Chief Financial Officer, Treasurer

Jean Franchi

Chief Operating Officer

Jonathan Yu

General Counsel

Rahul Khara